<div id="readability-page-1"><div>                     <div><h2>Key Points</h2><ul>   <li><strong>Insider sale:</strong> Xencor VP John Desjarlais sold 73,367 shares on December 19 at an average of $15.72 for $1,153,329.24, reducing his stake by 23.67% to 236,574 shares (valued at ~$3.72M).</li>   <li><strong>Mixed quarterly results:</strong> Xencor beat EPS estimates (‑$0.08 vs. ‑$0.72) but missed revenue expectations ($21.0M vs. $29.73M), with revenue up 18% year‑over‑year while the company remains unprofitable with negative net margin and ROE.</li>   <li><strong>Analyst view:</strong> The consensus is a &#34;Moderate Buy&#34; with an average price target of $24.88 after several upgrades and outperforms, though one firm (Weiss Ratings) retains a sell rating.</li> </ul></div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/xencor-inc-logo-1200x675.png/query-dj0yMDI0MDUwNzE1MjQwNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/xencor-inc-logo-1200x675.png/query-dj0yMDI0MDUwNzE1MjQwNQ"/>Xencor, Inc. (NASDAQ:XNCR - Get Free Report) VP John Desjarlais sold 73,367 shares of the firm's stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $15.72, for a total transaction of $1,153,329.24. Following the completion of the transaction, the vice president directly owned 236,574 shares in the company, valued at $3,718,943.28. This represents a 23.67% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink.</p><h2>Xencor Trading Down 1.5%</h2><p>NASDAQ:XNCR opened at $15.22 on Friday. The stock has a 50 day moving average of $15.51 and a 200-day moving average of $11.44. The firm has a market capitalization of $1.09 billion, a PE ratio of -8.60 and a beta of 0.96. Xencor, Inc. has a 52 week low of $6.92 and a 52 week high of $24.88. </p><p>Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.64. The business had revenue of $21.00 million during the quarter, compared to analyst estimates of $29.73 million. Xencor had a negative return on equity of 20.44% and a negative net margin of 87.14%.The business's revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.71) EPS.  As a group, analysts predict that  Xencor, Inc. will post -3.68 EPS for the current fiscal year. </p><h2>Analyst Upgrades and Downgrades</h2><hr/><hr/><p>XNCR has been the topic of a number of analyst reports. Cantor Fitzgerald increased their price objective on shares of Xencor from $40.00 to $42.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, November 6th. Truist Financial initiated coverage on shares of Xencor in a research note on Monday, November 24th. They issued a &#34;buy&#34; rating and a $29.00 price target on the stock. Royal Bank Of Canada lifted their price target on Xencor from $18.00 to $19.00 and gave the company an &#34;outperform&#34; rating in a report on Thursday, November 6th. Wedbush  reissued an &#34;outperform&#34; rating and issued a $26.00 price objective on shares of Xencor in a report on Thursday, November 6th. Finally, Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Xencor in a research report on Monday, December 22nd. Eight analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has given a Sell rating to the company's stock. According to MarketBeat, Xencor  has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $24.88.</p><p><b>Get Our Latest Analysis on Xencor</b></p><h2>Institutional Inflows and Outflows</h2><p>Large investors have recently bought and sold shares of the company. Amalgamated Bank raised its position in  Xencor by 4.8% in the third quarter. Amalgamated Bank now owns 20,846 shares of the biopharmaceutical company's stock worth $245,000 after acquiring an additional 947 shares in the last quarter.  HighVista Strategies LLC grew its stake in shares of  Xencor by 4.3% in the 2nd quarter. HighVista Strategies LLC now owns 33,304 shares of the biopharmaceutical company's stock worth $262,000 after purchasing an additional 1,362 shares during the last quarter.  GAMMA Investing LLC grew its stake in shares of  Xencor by 77.1% in the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 1,449 shares during the last quarter.  Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of  Xencor by 9.1% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,272 shares of the biopharmaceutical company's stock worth $144,000 after purchasing an additional 1,525 shares in the last quarter.  Finally, State of Tennessee Department of Treasury lifted its stake in  Xencor by 6.2% during the second quarter. State of Tennessee Department of Treasury now owns 30,721 shares of the biopharmaceutical company's stock valued at $241,000 after purchasing an additional 1,784 shares during the last quarter. </p><h2>About Xencor</h2><p> (Get Free Report)</p><p>Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.  </p><p>The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Xencor</li><li>Wall Street Stockpicker Names #1 Stock of 2026</li><li>ALERT: Drop these 5 stocks before January 2026!</li><li>The $650 Million Bet on AI's Future</li><li>Nvidia x 1,000,000</li><li>GOLD ALERT</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].</em></p>                     <div>                         <p>Insider Buying or Selling at Xencor?</p>                         <p>Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Xencor and related companies.</p>                                                                       </div>                                                               <div>                         <p>From Our Partners</p><div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251221095140_pushstock-2463798640.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251221095140_pushstock-2463798640.jpg"/></p><div><p>Wall Street Stockpicker Names #1 Stock of 2026</p><p>Do you own the worst stock of 2026? [Name + Ticker]  He issued warnings for RNG before it crashed 89%, BYND ...</p><p><span>Chaikin Analytics</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjgwMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjgwMQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251126120307_pushainewer-11.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251126120307_pushainewer-11.jpg"/></p><div><p>The $650 Million Bet on AI's Future</p><p>In 1999, Sutter Hill Ventures made a bold bet on Nvidia before anyone had heard of it. Now, they're going all-...</p><p><span>The Oxford Club</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQ4NQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjQ4NQ"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251223160054_pushdollar01.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251223160054_pushdollar01.jpg"/></p><div><p>The Best $1 You'll Spend This Holiday Season</p><p>Many individual traders are looking for ways to use AI tools that were once available only to large institutio...</p><p><span>Timothy Sykes</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjgzNg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjgzNg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://marketingassets.marketwise.com/prod/images/brownstoneresearch/et/2025/08_Aug/Jeff_Ripping_Bill_NO_GIF.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="500" height="500" original-src="https://imageproxy.pbkrs.com/https://marketingassets.marketwise.com/prod/images/brownstoneresearch/et/2025/08_Aug/Jeff_Ripping_Bill_NO_GIF.jpg"/></p><div><p>Jeff Brown's Prediction: Banks Replacing Dollars Soon</p><p>Do you have money in any of these banks?  Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp.  I...</p><p><span>Brownstone Research</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjM5OA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjM5OA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250723204149_pushainewer-6.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20250723204149_pushainewer-6.jpg"/></p><div><p>1 Hour Once A Day</p><p>My top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...</p><p><span>Base Camp Trading</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjM2Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjM2Mg"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/20251014140916_unnamed.png/query-MTc2MDQ2ODk1OTIxOA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="512" height="288" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/articles/20251014140916_unnamed.png/query-MTc2MDQ2ODk1OTIxOA"/></p><div><p>End of America update</p><p>There are five truths reshaping America’s financial future — and ignoring them could be costly. From an overex...</p><p><span>Porter &amp; Company</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjc0Ng?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjc0Ng"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://nlimgs.sfo2.cdn.digitaloceanspaces.com/2024/emailimgs/sacomfort.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="795" height="446" original-src="https://imageproxy.pbkrs.com/https://nlimgs.sfo2.cdn.digitaloceanspaces.com/2024/emailimgs/sacomfort.png"/></p><div><p>How Long Will $1M Last in Retirement?</p><p>Many people hope to retire with $1 million in savings, but how long will it really last?    The answer can...</p><p><span>SmartAsset</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjYyNA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjYyNA"/></p></div></div><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251126070338_pushainewer-14.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="200" height="200" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/thumb_20251126070338_pushainewer-14.jpg"/></p><div><p>Buy this $2 Gold Stock Before January 1, 2026</p><p>You need to own this company now - before the company’s scheduled production begins.</p><p><span>Golden Portfolio</span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjU3NA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xNjU3NA"/></p></div></div></div>                     </div>                 </div></div>

XNCR

<p>Xencor VP John Desjarlais sold 73,367 shares for $1,153,329.24, reducing his stake by 23.67%. Xencor's quarterly results showed a mixed performance, beating EPS estimates but missing revenue expectations. Analysts have a "Moderate Buy" consensus with a price target of $24.88. The stock opened at $15.22, with a market cap of $1.09 billion. Institutional investors have adjusted their positions in Xencor.</p>

Xencor (NASDAQ:XNCR) VP Sells $1,153,329.24 in Stock